US FDA Gets Another Appropriations Increase In FY 2020 House Bill
Overall percentage increase is not as high as the FY 2019 spending bill, but stakeholders are happy with the proposed boost in budget authority.
You may also be interested in...
The Center for Biologics Evaluation and Research may need more fee revenue to add employees to handle the increasing cell and gene therapy workload.
FY 2018 is first year that US FDA's device center got PDUFA funding for staffers; our infographic shows how CDER is getting an increasing proportion of user fee staff even as other sections of the agency have seen growth over the last five years.
Appropriations report directs the US FDA to offer the faster assessment and allow reliance on prior data submitted for applications caught in the transition from drug to biologic regulation.